Avid Bioservices Inc (CDMO)

[cheynew]

AACR abstracts online now. I did a search for Bavituximab but nothing came up. Peregrine has Booth #2318.

http://www.abstractsonline.com/Plan/SSResults.aspx

The only one I found that Peregrine is involved in is:

Abstract Number: 5116
Presentation Title: Phosphatidylserine-targeting antibodies augment anti-tumor activity of PD-1 antibodies and alter immuno-profiles in murine triple negative breast cancers
Presentation Time: Wednesday, Apr 20, 2016, 8:00 AM -12:00 PM
Location: Section 31
Poster Board Number: 2
Author Block: Michael J. Gray1, Jian Gong1, Ryan N. Parks1, Michaela M.S. Hatch2, Van Nguyen1, Christopher C.W. Hughes2, Jeff T. Hutchins1, Bruce D. Freimark1. 1Peregrine Pharmaceuticals, Inc., Tustin, CA; 2University of California, Irvine, CA
Abstract Body: Current treatments for triple negative breast cancers rely primarily upon surgical intervention and chemotherapy. Unfortunately, chemotherapies have the propensity to help establish an immunosuppressive condition in part though exposure of phosphatidylserine (PS) in the tumor microenvironment. We demonstrate that treatment of the murine triple negative breast cancer E0771 using a PS-targeting antibody inhibits in vivo growth, and significantly enhances the anti-tumor activity of antibodies directed to the checkpoint inhibitor PD-1. Combinational treatment by antibodies targeting PS and PD-1 increased the number of tumor infiltrating lymphocytes (TILs) to a greater extent than observed with single-arm therapies. Furthermore, combination of PS and PD-1 targeting antibodies provides a distinct survival advantage over treatment by either agent alone, which correlates with an increase in complete tumor regression and the onset of a durable immune mediated response capable of rejecting a secondary challenge by the same tumor. Finally, immune-profiling analysis of tumor RNA using Nanostring revealed that the combination antibody therapy enhanced immune regulatory pathways including MHC class I/II expression, antigen processing and presentation, and leukocyte and macrophage functions. Combined, our data suggest that in triple negative breast cancers antibody therapy blocking PS-associated immunosuppression may further enhance immunotherapies directed at immune checkpoint inhibitors, including those targeting the PDL-1/PD-1 axis.